The FDA’s Paxlovid Pandemonium
Not only was evidence of failure deliberately ignored; prospective testing methodologies were altered mid-trial to favor a positive outcome when it became apparent that the Paxlovid trial results would not meet their original endpoints. In fact, Pfizer had already opted to halt its Paxlovid trial when it saw that it didn’t work.